Technology Appraisal Virtual Committee Meeting

Committee B

Zoom

# Minutes: Confirmed

## Date and Time: Wednesday 9 September 2020 09.30 - 4.30pm

### Present:

1. Professor Amanda Adler (Chair) Present for all notes
2. Dr Sanjeev Patel (Vice-Chair) Present for all notes
3. Dr Laura Bojke Present for all notes
4. Dr Mark Glover Present for all notes
5. Dr Megan John Present for all notes
6. Professor Sanjay Kinra Present for all notes
7. Dr Nicholas Latimer Present for all notes
8. Ms Anna Pracz Present for all notes
9. Dr Stephen Smith Present for all notes
10. Professor Nicky Welton Present for all notes
11. Mr Nigel Westwood Present for all notes
12. Mr Peter Wheatley Price Present for notes 9 to 13
13. Professor Sarah Wild Present for all notes
14. Dr Ed Wilson Present for all notes
15. Dr Stuart Williams Present for all notes
16. Mr Tony Wootton Present for all notes

### In attendance:

* Nicole Elliott, Associate Director, NICE, Present for notes 1 to 9 and 18 to 19
* Ross Dent, Associate Director, NICE, Present for notes 10 to 17
* Jeremy Powell, Project Manager, NICE, Present for notes 1 to 9
* Joanne Ekeledo, Project Manager, NICE, Present for notes 10 to 19
* Mira Patel, Administrator, NICE, Present for all notes
* Rashida Akhtar, Administrator, NICE, Present for notes 10 to 19
* Laura Marsden, Coordinator, NICE, Present for all notes
* Mary Hughes, Technical Analyst, NICE, Present for notes 1 to 9
* Peter O’Neill, Technical Adviser, NICE, Present for notes 1 to 9
* Graham Scotland, Aberdeen HTA Group, Evidence Review Group, Present for notes 1 to 5
* Miriam Brazzelli, Aberdeen HTA Group, Evidence Review Group, Present for notes 1 to 5
* Charlotte Kennedy, Aberdeen HTA Group, Evidence Review Group, Present for notes 1 to 5
* David Cooper, Aberdeen HTA Group, Evidence Review Group, Present for notes 1 to 5
* Peter Auguste, Warwick Evidence, Evidence Review Group, Present for notes 10 to 14
* Amy Grove, Warwick Evidence, Evidence Review Group, Present for notes 10 to 14
* Mubarak Patel, Warwick Evidence, Evidence Review Group, Present for notes 10 to 14
* Prof Amit Bahl, Clinical Expert, Consultant Oncologist, Present for notes 1 to 4
* Prof Heather Payne, Clinical Expert, Consultant in Clinical Oncology and Professor of Prostate Cancer, Present for notes 1 to 4
* Mrs Meg Burgess, Patient Expert, Specialist Nurse, Prostate Cancer UK, Present for notes 1 to 4
* Dr Stephen Allen, Patient Expert, Tackle Prostate Cancer, Present for notes 1 to 4
* Prof Peter Clark, Cancer drugs Fund Clinical Lead, Present for notes 1 to 9

### Non-public attendees:

* Helen Barnett, Senior Medical Editor, NICE, Present for notes 10 to 17
* Ann Greenwood, Editor, NICE, Present for notes 1 to 9
* Claire Hawksworth, Managed Access Team, NICE, Present for notes 18 to 19
* Thomas Lawrence, Managed Access Team, NICE, Present for notes 18 to 19
* Edgar Masanga, Business Analyst, NICE, Present for all notes
* Catherine Pank, Corporate Office Coordinator, NICE, Present for notes 1 to 4 and 10 to 14
* Ines Ribeiro, SHTAC ERG, Present for notes 1 to 4
* Irina Tikhonova, SHTAC ERG, Present for notes 1 to 4
* Mandy Tonkinson, Public Involvement adviser, NICE, Present for notes 1 to 4

## Notes

### Any other Business

1. None.

### Minutes from the last meeting

1. The committee approved the minutes of the committee meeting held on 13 August 2020.

## Appraisal of darolutamide with androgen deprivation therapy for treating non-metastatic hormone-relapsed prostate cancer [ID1443]

### Part 1 – Open session

1. The Chair welcomed the invited clinical and patient experts, Evidence Review Group (ERG)/Assessment Group (AG) representatives and representatives from Bayer.
2. The Chair asked all committee members, experts, ERG/AG representatives and NICE staff present to declare any relevant interests  
   1. Professor Amit Bahl declared a direct financial interest as he has sat on advisory boards for Bayer and comparator companies.
      1. It was agreed that this declaration would not prevent him from participating in this section of the meeting.
   2. Professor Heather Payne declared a direct financial interest as she has received honorarium for presenting data in 2 scientific prostate cancer meetings sponsored by Bayer. The topics did not include this medication.
      1. It was agreed that this declaration would not prevent her from participating in this section of the meeting.
   3. Dr Stephen Allen declared an indirect professional financial interest as his organisation Tackle Prostate Cancer receive unrestricted medical grants from several pharmaceutical companies, however have not received funding from a company that manufacture of darolutamide in the previous twelve months.
      1. It was agreed that this declaration would not prevent him from participating in this section of the meeting.
   4. Mrs Meg Burgess declared an indirect professional financial interest as her organisation Prostate Cancer UK received funding from pharmaceutical companies, including Bayer in the last twelve months.
      1. It was agreed that this declaration would not prevent her from participating in this section of the meeting.
   5. Prior to the meeting Peter Wheatley Price declared a direct financial interest as he is employed by Takeda who manufacture potential competitor products.
      1. It was agreed that this declaration would prevent him from participating in this section of the meeting.
   6. No further conflicts of interest were declared for this appraisal.
   7. The Chair introduced the lead team who gave presentations on the clinical effectiveness and cost effectiveness of the treatment.
   8. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

### Part 2a – Closed session (company representatives, clinical and patient experts and members of the public were asked to leave the meeting)

1. The committee discussed confidential information submitted as part of this appraisal.

### Part 2b – Closed session (ERG/AG representatives were asked to leave the meeting)

1. The committee discussed confidential information submitted as part of this appraisal.
2. Agreement on the content of the Final Appraisal Determination (FAD) was discussed by the committee.
3. The committee decision was based on consensus.
4. The committee asked the NICE technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.

## Appraisal of siponimod for treating secondary progressive multiple sclerosis [ID1304]

### Part 1 – Open session

1. The Chair welcomed the invited clinical and patient experts, Evidence Review Group (ERG)/Assessment Group (AG) representatives and representatives from Novartis Pharmaceuticals (UK) Ltd.
2. The Chair asked all committee members, ERG representatives and NICE staff present to declare any relevant interests.
3. No conflicts of interest were declared for this appraisal.
4. The Chair introduced the key themes arising from the consultation responses to the Appraisal Consultation Document (ACD) received from consultees, commentators and through the NICE website.
5. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

### Part 2 – Closed session (company representatives, ERG/AG representatives and members of the public were asked to leave the meeting)

1. Agreement on the content of the Final Appraisal Determination (FAD) was discussed by the committee.
2. The committee decision was based on consensus.
3. The committee asked the NICE technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.

## Appraisal of caplacizumab for treating adults experiencing an episode of acquired thrombotic thrombocytopenic purpura [ID1185]

### Part 2 only – Closed session (company representatives, clinical and patient experts, ERG/AG representatives and members of the public were not present for this section of the meeting).

1. Prior to the meeting Peter Wheatley Price declared a direct financial interest as he is employed by Takeda who manufacture potential competitor products.
   * 1. It was agreed that this declaration would prevent him from participating in this section of the meeting.
2. The committee discussed confidential information submitted as part of this appraisal.